AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06492031 — intervention group
Intervention type: DRUG
Intervention: Glucose Peritoneal Dialysis Solution
Description: The treatment modality, number of daily dialysate exchanges, dialysate concentration, exchange dosage of dialysate, duration of dwell, and length of treatment for PD patients as determined by the clinician.
Study NCT06219603 — intervention group
Intervention type: OTHER
Intervention: survey
Description: questions around socio-demographic information, including age, sex, marital status, residency, education level, and employment status. After that, specific questions were asked to measure the level of knowledge and awareness about rheumatic diseases
Study NCT05603143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeldesivir
Description: Tablets administered orally without regard to food.
Study NCT05006040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Closed Loop System
Description: Participants will utilize the Tandem Control-IQ Professional Hybrid Closed Loop artificial pancreas system \[25, 26\]. This device consists of the Dexcom G6 Continuous glucose monitor (or a more recent interoperable CGM), the Tandem t:slim X2 continuous subcutaneous insulin infusion pump, and the Control-IQ professional hybrid closed loop control algorithm. The CGM is generally replaced by parents or patients and then replaced after sensor expiration or if it falls off. This CGM, like all future iCGMs, is factory calibrated and approved for direct dosing of insulin. In addition, while the system is in use, patients will conduct blood glucose level checks at least four times a day with a fingerstick and calibrate the CGM if the measurements differ by more than 20 mg/dL of fingerstick blood glucose level. The t:slim X2 insulin pump delivers rapid acting insulin via a subcutaneous cannula which is placed by parents or patients and then replaced every 3 days \[30\].
Study NCT05222711 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of the PICO(TM) monitoring device
Description: The aim is to record if the outcome (referral or not) is influenced by the results of the parameters and/or the ECG.
Study NCT06265415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: it contains both selective, competitive, alpha1-adrenergic antagonism and non-selective, competitive, beta-adrenergic (B1 and B2) blocking activity in a single agent
Study NCT06265415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerine
Description: a nitric oxide donor with low oral bioavailability and a very short half-life, has a potent venodilator effect in low doses and affects arterial tone at high doses
Study NCT06265415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: dihydropyridine calcium channel blocker. Its main uses are as an antianginal and antihypertensive
Study NCT04906876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel as a 60-minute IV infusion
Study NCT04906876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: 9-ING-41 as an IV infusion over 1-4 hours twice weekly
Study NCT05600023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Description: Nitrofurantoin has been found to successfully eradicate gram-negative bacteria such as Enterococcus faecalis that one of the most important bacteria in endodontic lesions
Study NCT05600023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double Antibiotic
Description: DAP is a combination of two antibiotics which are ciprofloxacin and metronidazole
Study NCT06009588 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: self-expandable valves
Description: patients undergoing TAVR use self-expandable valves
Study NCT06009588 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon-expandable valves
Description: patients undergoing TAVR use balloon-expandable valves
Study NCT04635774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: 40 IU via four activations of an intranasal spray
Study NCT04635774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Four activations of an intranasal spray containing placebo (normal saline).
Study NCT05313373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: In addition to the routine procedure, virtual reality glasses will be applied to the women in the virtual reality group of the research. Virtual reality glasses is a device that works on compatible smart mobile phones. After being taken to the gynecological table for the HSG procedure, the women included in the experimental group will be made to watch a video lasting an average of 10 minutes with virtual reality glasses until the procedure is completed. While watching the video, the relaxing music of the video will be played.
Study NCT04642612 — intervention group
Intervention type: DEVICE
Intervention: TCD Measurement
Description: CBFV measurements will be acquired continuously with the patient supine and the head neutral. Analysis of CBFV measurements will be undertaken at 3 timepoints:~1. Patient awake and supine in the holding area~2. After sedation~3. After interscalene nerve block
Study NCT05271071 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided piriformis muscle and gluteus maximus muscle lidocaine injection
Description: Ultrasound guided piriformis muscle (piriformis syndrome) and gluteus maximus muscle 5 ml %1 lidocaine injection
Study NCT05603143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Obeldesivir Placebo
Description: Placebo tablets administered orally without regard to food.
Study NCT06442423 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Psilocybin
Description: Psilocybin will be administered in an opaque, size 2 gelatin capsule with approximately 180 ml of water to be orally ingested at Visit 5. The dose of psilocybin will be 25 mg.This is an open-label clinical trial with a single treatment arm. This is an open-label clinical trial with no blinding.
Study NCT06479135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navtemadlin
Description: Navtemadlin is an investigational MDM2 inhibitor
Study NCT06479135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Navtemadlin placebo
Description: Navtemadlin placebo
Study NCT06479135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib is a janus kinase 1/2 inhibitor
Study NCT06479135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib
Description: Ruxolitinib is a janus kinase 1/2 inhibitor
Study NCT04398316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Iv
Description: 2 mg/kg over 5 minutes
Study NCT04398316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HYDROmorphone Injection
Description: 1 mg over 5 minutes
Study NCT06396559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pre test-post test
Description: The mobile application will be installed on the mobile devices of student nurses and its effectiveness will be tested.
Study NCT05613127 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boryung Hepatitis A Vaccine Pre-Filled Syringe Inj. 0.5 mL
Description: Dosage and administration: pre-iflled syringe, IM injection of 0.5mL will be given for 2 times with 6-months interval.
Study NCT05613127 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HAVRIX 720 Junior 0.5 mL
Description: Dosage and administration: pre-filled syringe, IM injection of 0.5mL will be given for 2 times with 6-months interval.
Study NCT05853965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin, Venetoclax
Description: Belantamab mafodotin (IV) Venetoclax (PO)
Study NCT05748197 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADCLEC.syn1 CAR T cells
Description: There are 4 planned flat-dose levels: 25 × 10\^6, 75 × 10\^6 , 225 × 10\^6 , and 450 × 10\^6 CAR T cells and 1 de-escalation dose: 10 × 10\^6 CAR T cells.
Study NCT05748197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning chemotherapy
Description: Fludarabine 30 mg/m2 daily for 3 days and cyclophosphamide 500 mg/m2 daily for 3 days.
Study NCT05038124 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative Stereotactic Body Radiotherapy (SBRT)
Description: Target lesions will be treated with preoperative SBRT consisting of biologically effective dose (BED10) of 50.4 - 81.6 Gy delivered in either three fractions or a single fraction.
Study NCT06089629 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lingual frenuloplasty
Description: Surgical release of ankyloglossia with suture reorientation of the wound to improve lingual mobility, done under local or general anesthesia
Study NCT05875207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based practice
Description: Physical therapists who are randomized to this arm will receive mindfulness training. This training will teach physical therapists to use the following with their patients: 1) use mindfulness to strengthen self-regulation of habitual and compulsive opioid use, and to mitigate pain by reinterpreting these experiences as innocuous sensory information, 2) use reappraisal to reframe stressors and maladaptive thoughts to decrease negative emotions and engender meaning in life, 3) use savoring of pleasant events and pleasurable sensations to enhance positive emotions and reward and, 4) to integrate mindfulness, reappraisal and savoring with evidence-based physical therapy.
Study NCT05875207 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control/Standard Physical Therapy
Description: Physical therapists randomized to this arm will receive no additional training and will provide standard care to patients with chronic musculoskeletal pain and long-term opioid treatment. Patients with chronic musculoskeletal pain and long-term opioid treatment who seek care from a physical therapist in this arm will be approached to participate in the study. If eligible and willing to participate in the study they will be asked questions about their pain and opioid use before and after treatment. We plan on enrolling 2 patients for each physical therapist.
Study NCT05929430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness program
Description: Six weeks mindfulness program. The program is explained in arm descriptions.
Study NCT05929430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness program with Virtual Reality
Description: Six weeks mindfulness program. The program is explained in arm descriptions.
Study NCT06049654 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NVT ALLEGRA TAVI System TF
Description: Transcatheter aortic valve implantation of a NVT ALLEGRA TAVI System TF in patients with severe haemodynamical valve deterioration of a biological aortic valve implanted surgically
Study NCT06049654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EDWARDS SAPIEN 3 or SAPIEN ULTRA SYSTEM
Description: Transcatheter aortic valve implantation of an EDWARDS SAPIEN 3 SYSTEM in patients with severe haemodynamical valve deterioration of a biological aortic valve implanted surgically
Study NCT05608083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEARTS classes
Description: HEARTS teaches autistic adults about friendship and healthy dating relationships. HEARTS is 6-sessions long and meets weekly over zoom. Each session is 90 minutes long.
Study NCT05608083 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online discussion group
Description: A 90-minute discussion group will meet online weekly for 6 weeks to discuss friendships and healthy dating relationships for autistic adults.
Study NCT06435832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Absorbable Gelatin
Description: After tooth extraction, only saline irrigation was applied and a absorbable gelatin sponge was placed in the socket.
Study NCT06435832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: After tooth extraction, after irrigation with saline, 2% chlorhexidine gel was absorbed into gelatin sponges and placed into the socket.
Study NCT06435832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: Tranexamic acid 50mg/ml for injection after saline irrigation after tooth extraction solution into gelatin sponges was applied to the socket after it was cured.
Study NCT05150990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Older adults (residents of senior living communities) will engage in four 20-minute virtual reality activities (via the Rendever platform) with their adult child each week for 4 consecutive weeks. The 4 sessions will include immersive virtual adventures (e.g., bucket list travel) and reminiscence activities (e.g., virtual life story). Adult children will be participating remotely from their own homes.
Study NCT05150990 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Chat
Description: Older adults (residents of senior living communities) will engage in four 20-minute video chat sessions (via the Zoom platform) with their adult child each week for 4 consecutive weeks. Adult children will be participating remotely from their own homes.
Study NCT06100289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV injection.
Study NCT06100289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab SC
Description: Vedolizumab SC injection.
Study NCT05282927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implementation Strategy: Foundational REP
Description: The goal is to test implementation intensification approaches for group PT sites that have not met implementation adoption benchmarks, specifically Foundational REP vs. Enhanced REP. The investigators propose that low intensity implementation support that promotes adapting Group PT for context and provides tools for ongoing evaluation (defined as foundational REP), will be sufficient for some but not all sites to successfully implement group PT as a clinical service.
Study NCT05282927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation Strategy: Enhanced REP (enREP)
Description: The goal is to test implementation intensification approaches for sites that have not met implementation adoption benchmarks, specifically Foundational REP vs. EnREP. The investigators posit that monitoring sites' progress and adding, for sites with low adoption, higher intensity strategies (defined as EnREP) that directly influence teams' capacity and skills to effectively self-organize and problem-solve will lead to higher implementation adoption, penetration, fidelity, and value.
Study NCT06158724 — intervention group
Intervention type: OTHER
Intervention: Personal Protective Equipment
Description: Simplified PPE for use in COVID-19 departments.
Study NCT04438213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
Study NCT04438213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metolazone
Description: Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
Study NCT04438213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
Study NCT05031273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Residents moving into a congregate-living development with more features that support healthy living
Description: Our team is making evidence-based recommendations to the developer and design team of an upcoming congregate-living development to support the physical activity, healthy eating, and social connections of residents moving into the new building(s). We hope for the developer to integrate into the new building(s) as many as possible of our team's built environment design and amenity recommendations into their site and/or building plans. Additionally, discussions with the municipality are also occuring on built environment design and amenity recommendations to improve the neighbourhood surrounding the site. Although our team has provided these recommendations, it is ulimatily up to the discretion of the developer and the municipality as to whether and what design and amenity changes are made.
Study NCT04686604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best practice alert for the notification of patient HFrEF and recommended evidence-based medical therapies (NO drugs are being administered in this trial)
Description: Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction, most recent blood pressure and heart rate, most recent potassium and estimated glomerular filtration rate, and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
Study NCT04898387 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bimatoprost Timolol (T4030)
Description: Eye drop
Study NCT04898387 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost Timolol (Ganfort)
Description: Eye drop
Study NCT05400824 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood, DNA, feces, urine, hair and skin microbiota collection
Description: See above
Study NCT04967456 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Measurement of pulpal blood flow of traumatised tooth
Description: Measurement of the blood flow of the dental pulp will be performed, using a laser doppler flow monitor mVMS-LDF2TM (Moor Instruments Ltd Millwey Axminster Devon, UK), emission wavelength 785nm±10nm, dual-channel laser Doppler monitoring option. Two probes will be used, each consisting of one afferent and one efferent optic fiber to conduct the light to and from the tooth surface. The probe is stainless steel needle-like tube, which is 10-80 mm long and 1.5 mm in the diameter. The utilised parameter settings will be: Average power - 1.0 mV; Diameter of the probe - 1.5 mm; Frequency - 40 Hz; Monitoring time-180 seconds (sec)
Study NCT04967456 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of pulpal blood flow of traumatised tooth
Description: Measurement of the blood flow of the dental pulp will be performed, using a laser doppler flow monitor mVMS-LDF2TM (Moor Instruments Ltd Millwey Axminster Devon, UK), emission wavelength 785nm±10nm, dual-channel laser Doppler monitoring option. Two probes will be used, each consisting of one afferent and one efferent optic fiber to conduct the light to and from the tooth surface. The probe is stainless steel needle-like tube, which is 10-80 mm long and 1.5 mm in the diameter. The utilised parameter settings will be: Average power - 1.0 mV; Diameter of the probe - 1.5 mm; Frequency - 40 Hz; Monitoring time-180 seconds (sec)
Study NCT06111027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibro-tactile stimulation
Description: Vibro-tactile stimulation is a non-invasive treatment option. As stimulators, we will apply a pair of light-weight encapsulated cylindrical vibrators to both sides of the larynx (voice box). The vibration frequency for VTS will set be to 100Hz and the participant may feel a mild tingling or vibrating sensation during VTS. The participants will be asked to apply for VTS at home over a period of 8 weeks. The participants will be asked to use this device for 3 days in the first week, 4 days in the second week, 5 days in the third week and 6 days in the fourth week. During the last 4 weeks, the participants will apply VTS on self-selected days as needed, not exceeding 6 times a week, to control and improve symptoms.
Study NCT06267911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation and psychological support (RGS-ICU)
Description: The RGS-ICU intervention consists of daily 20-minute sessions of early cognitive stimulation and psychological support adjuvant to standard ICU care administered by research staff and supervised by clinical staff each morning in the patient's own room during ICU admission and until ICU discharge or up to a maximum of 28 days after randomization. The sessions consist of orienting the patient to space and time, cognitive training of attention, working memory, learning/memory, executive function and processing speed, viewing of relaxing videos inspired by nature and fantasy scenarios to reduce stress and anxiety, and psychoeducation about the ICU environment and the characteristics of the cognitive, mental and physical state of critically ill patients.
Study NCT06115954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Management Supported Telerehabilitation
Description: Supporting the exercises with an internet-based environment and self-management training for Children and Adolescents with Juvenile Idiopathic Arthritis
Study NCT05715541 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: mobile applications with the name Set My INR
Description: The relevant software company assisted in developing the phone application. The language of the application created with the name Set My INR is Turkish. The application provided an opportunity for patients to share and communicate with their physician after having the INR value measured in a health institution near their place of residence before coming to the hospital
Study NCT06115954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Management Supported Telerehabilitation
Description: Supporting the exercises with an internet-based environment and self-management training for Children and Adolescents with Juvenile Idiopathic Arthritis